Microdosing

In healthcare B2B sales, the deal is often shaped before ROI is fully debated. It begins when a buyer asks a simpler question: what could go wrong? Healthcare sales is methodical, slow, and process heavy. Health systems are not optimized for novelty or speed alone. They are optimized to avoid harm while maintaining continuity of care. Safety may not sound exciting, but for anyone selling into a ho...

No one wakes up hoping to use a hospital. Patients do not browse health systems the way they browse airlines, hotels, or retailers. They do not long for novelty, delight, or emotional connection in the usual sense. They arrive when something hurts, when something feels wrong, or when uncertainty becomes too heavy to ignore. In healthcare, usage is driven by need, not desire.  This distinction chan...

Why platforms, platform-aligned solutions, and upgrade portfolios are replacing standalone products. Healthcare is entering a phase where the economics of growth have fundamentally changed. The companies scaling fastest are not launching more features, more products, or more narrowly defined point solutions. Instead, they are making a different kind of investment by building platforms designed for...

Healthcare innovation still loves elegant stories. Unfortunately, elegant stories don’t get funded when budgets are constrained. For years, the industry has relied on value narratives that sound reasonable but collapse under scrutiny. The most common failure is distance in the value chain. They often sound like: “If imaging quality improves, outcomes improve. If outcomes improve, costs go down.” E...

Healthcare innovation still loves elegant stories. Unfortunately, elegant stories don’t get funded when budgets are constrained. For years, the industry has relied on value narratives that sound reasonable but collapse under scrutiny. The most common failure is distance in the value chain. They often sound like: “If imaging quality improves, outcomes improve. If outcomes improve, costs go down.” E...

If you’ve attended any healthcare conference, a pattern emerges so consistently that it becomes impossible to ignore: healthcare is not suffering from a lack of innovation. It is suffering from an oversupply of disconnected innovations, where each one is well-intentioned, each one promising value, and each one adding yet another layer to an already unmanageable tech landscape.

The US healthcare system is privatized and built around a capitalist model. Within that framework, one flaw stands out: unlike nearly every other high-performing health system in the world, the United States lacks a true backbone. There is no layer that reliably guides people, connects decisions over time, or helps them confidently take the next step. The solution is the backbone it never built, a...

Healthcare does not lack workers; it lacks a work model capable of supporting them. Modern care assumed infinite elasticity from clinicians, but that model has reached its limit. What comes next is not incremental change; it is reconfiguration: team-based, patient-centered, digitally enabled, and economically aligned with value. When the work is redesigned, the workforce stabilizes. This necessary...

The complexity of the U.S. healthcare system is magnified by inconsistent, fragmented naming of care locations. Terms such as hospital, medical center, and institute may appear interchangeable, but in practice they introduce confusion, increase the risk of surprise billing, and fuel costly administrative errors. 

Every healthcare organization operates within a web ofoverlapping experience maps, including clinical, administrative, payer, patient, and policy maps. These maps shape every decision, workflow, and outcome. In healthcare, a customer experience (CX) map traces the steps, systems, and emotions that patients, clinicians, and staff move through as care is delivered and supported. Each map makes sense...

Every industry has a process that looks small on paper butshapes everything around it. In healthcare, that process is priorauthorization. It is the quiet monster that hides between doctors, payers, and patients, invisible to most until it strikes. When it does, it does not just delay care; it unravels trust, burns out staff, and corrodes the very idea of a coordinated patient journey.

Hospitals were once the epicenter of healthcare food service. One kitchen fed thousands, one cafeteria served everyone from physicians to visitors, and one model defined the experience. That era is ending. As care moves beyond the hospital walls into outpatient clinics, ambulatory centers, imaging hubs, and patients’ homes, food service needs to move with it. What once was a static operation is be...

For years, the story of American healthcare has read like an obituary for small, independent medical practices. Faced with shrinking reimbursements, staffing shortages, and rising administrative burden, many physicians traded autonomy for stability, selling to health systems or private equity. Yet beneath the consolidation headlines, a quiet rebellion is taking shape. Across the country, small spe...

All around you, Healthcare leadership continues to lean on familiar solutions: more education, more empowerment, more reminders to improve adherence. It sounds polite,nonthreatening, and promising. But it’s also a comfortable excuse that obscures a deeper, systemic failure. Because the truth is: medication adherence—our most basic measure of patient engagement—remains stubbornly low. Despite decad...

Modern Primary Care Diagnostic Sequences; Why the Future of Care Hinges on Faster, Smarter Diagnostics. Traditionally, and still in many practices today, some of the most important parts of a primary care visit happen after the patient leaves the exam room. Diagnosis is often delayed, follow-up decisions are disconnected from the visit itself, and early opportunities for intervention can be missed...

As demand for GLP-1 drugs like Ozempic and Wegovy soars, a parallel market for compounded versions has emerged — one that’s largely unregulated and increasingly risky. This episode examines how gaps in oversight, aggressive marketing, and blurred lines between compounding and manufacturing expose patients to safety concerns and strain the health system. We explore why compounded GLP-1s are more th...

Medicaid and Medicare Advantage may seem like programs for specific groups, but the choices made in these public plans ripple across the entire insurance system. This episode explores how coverage churn, capped benefits, and financing reforms in public programs ultimately shape commercial premiums, provider networks, and patient access for everyone. We unpack why what starts in Medicaid and Medica...

Primary care consolidation is changing how patients experience — and pay for — everyday healthcare. This episode examines how ownership, pricing, and place intersect to drive up costs, with research from The Journal of the American Medical Association showing that hospital and private equity–affiliated practices charge more without delivering clear quality gains. We unpack what this hidden shift m...

Firearms have become the leading cause of death among U.S. children and teens, yet unlike cars, toys, or even e-cigarettes, they remain exempt from basic consumer safety regulation. This episode explores the public health and economic costs of treating guns as constitutionally protected products rather than consumer goods, drawing on recent research and commentaries from The Journal of the America...

Patients are no longer entering care through the doors traditional health systems control. This episode explores how retail brands, pharma platforms, and digital experiences are becoming the new “front doors,” transferring trust and reshaping where care journeys begin. We look at what this shift means for partnerships, brand equity, and how healthcare organizations must adapt to stay relevant at t...

Rising clashes between hospitals and insurers are exposing outdated fee-for-service infrastructure. As payer–provider clashes surge, healthcare infrastructure is under pressure. We unpack what’s fueling these disputes, how they impact patients, and why flexible platforms may be the key to moving forward.

From weight loss buzz to healthcare infrastructure, GLP-1 drugs started as diabetes treatments but are now reshaping weight loss, care delivery, and consumer markets. In this episode, we explore how they have become more than medicine, driving new business models, digital access points, and patient expectations, featuring insights from leaders across health plans, startups, and strategy firms.

Microdosing is adjusting its format. This episode gives listeners a sneak peek at how Microdosing will be adopting a report-based, written-format-first approach to content. And be moving deeper into the 21st century by having those reports converted to audio podcasts using our new AI-based narrator, Mavis.

For years, the story of American healthcare has read like an obituary for small, independent medical practices. Faced with shrinking reimbursements, staffing shortages, and rising administrative burden, many physicians traded autonomy for stability, selling to health systems or private equity. Yet beneath the consolidation headlines, a quiet rebellion is taking shape. Across the country, small spe...

We interviewed a group of terrific product leaders during this time. Looking back, here are a few of our observations.